ライフサイエンスコーパス: severe aortic stenosis

1 high-risk operable patients with symptomatic severe aortic stenosis.

2 ring exercise and hyperemia in patients with severe aortic stenosis.

3 to hemodynamic improvement in patients with severe aortic stenosis.

4 n symptomatic and asymptomatic patients with severe aortic stenosis.

5 central concept in the care of patients with severe aortic stenosis.

6 timate of aortic valve area in patients with severe aortic stenosis.

7 treatment option for high-risk patients with severe aortic stenosis.

8 ion for treatment of high-risk patients with severe aortic stenosis.

9 ociated with poor prognosis in patients with severe aortic stenosis.

10 ow Medical (DFM) system for the treatment of severe aortic stenosis.

11 ve to high- or intermediate-risk surgery for severe aortic stenosis.

12 eplacement (TAVR) in high-risk patients with severe aortic stenosis.

13 ive in high-risk or inoperable patients with severe aortic stenosis.

14 ry artery disease is common in patients with severe aortic stenosis.

15 portant goals of treatment for patients with severe aortic stenosis.

16 APIEN XT transcatheter heart valve (ESV) for severe aortic stenosis.

17 is preferred for patients with cirrhosis and severe aortic stenosis.

18 stic importance of the KCCQ in patients with severe aortic stenosis.

19 and prohibitive surgical risk patients with severe aortic stenosis.

20 ely) in high-risk patients with symptomatic, severe aortic stenosis.

21 therapeutic decision making of patients with severe aortic stenosis.

22 (TAVR) to low-risk patients with symptomatic severe aortic stenosis.

23 and equilibrium MR imaging in patients with severe aortic stenosis.

24 ified patients with symptomatic low-gradient severe aortic stenosis.

25 and in patients with conventionally defined severe aortic stenosis.

26 ption for valve replacement of patients with severe aortic stenosis.

27 ity, and validity of CT-FFR in patients with severe aortic stenosis.

28 n (TAVI) is a novel therapy for treatment of severe aortic stenosis.

29 R) has long been the mainstay of therapy for severe aortic stenosis.

30 lantation (TAVI) for high-risk patients with severe aortic stenosis.

31 come of Ex-PHT in asymptomatic patients with severe aortic stenosis.

32 nt option for elderly women with symptomatic severe aortic stenosis.

33 ement (AVR) is the established treatment for severe aortic stenosis.

34 with a stented porcine valve in adults with severe aortic stenosis.

35 re left ventricular systolic dysfunction and severe aortic stenosis.

36 use has not been validated in patients with severe aortic stenosis.

37 nificantly different from that of concordant severe aortic stenosis.

38 CT-FFR is safe and feasible in patients with severe aortic stenosis.

39 t option for older patients with symptomatic severe aortic stenosis.

40 nical outcomes in patients with asymptomatic severe aortic stenosis.

41 HCM could not be made because of concomitant severe aortic stenosis.

42 onized management of high-risk patients with severe aortic stenosis.

43 dynamic burden in patients with asymptomatic severe aortic stenosis.

44 than in patients with conventionally defined severe aortic stenosis (28 +/- 5 mm vs. 31 +/- 5 mm), an

45 Eight patient-specific models of severe aortic stenosis (6 tricuspid and 2 bicuspid) were

46 Among patients with asymptomatic severe aortic stenosis, a strategy of early TAVR was sup

47 iographic findings in low-risk patients with severe aortic stenosis after surgical aortic valve repla

48 s undergoing TAVI, 433 (71.4%) patients with severe aortic stenosis and a preprocedural right heart c

49 Among patients with severe aortic stenosis and a small aortic annulus who un

50 r-initiated trial in high-risk patients with severe aortic stenosis and an anatomy suitable for the t

51 al aortic-valve replacement in patients with severe aortic stenosis and an increased risk of death du

52 ized 241 high-risk patients with symptomatic severe aortic stenosis and anatomy suitable for treatmen

53 at 5 years, in a real-world population with severe aortic stenosis and at low and intermediate risk,

54 Many patients with severe aortic stenosis and coexisting conditions are not

55 for the treatment of high-risk patients with severe aortic stenosis and coexisting illnesses.

56 M system in surgical high risk patients with severe aortic stenosis and complex anatomy aortic regurg

57 Among patients with symptomatic severe aortic stenosis and comprehensive sarcopenia and

58 nts are universally present in patients with severe aortic stenosis and comprise approximately half o

59 low-ejection fraction, low-gradient (LEF-LG) severe aortic stenosis and concomitant relevant mitral r

60 A total of 125 patients with severe aortic stenosis and ejection fraction >40% schedu

61 ose monitoring of patients with asymptomatic severe aortic stenosis and help to validate current guid

62 atheter Valves) trial in which patients with severe aortic stenosis and high surgical risk were rando

63 In patients with severe aortic stenosis and high surgical risk, PPM is mo

64 ic valve replacement (AVR) for patients with severe aortic stenosis and high surgical risk.

65 R is an alternative to AVR for patients with severe aortic stenosis and high surgical risk.

66 c valve replacement (SAVR) for patients with severe aortic stenosis and high surgical risk.

67 LF is common in severe aortic stenosis and independently predicts mortal

68 ic valve replacement (SAVR) in patients with severe aortic stenosis and intermediate or high surgical

69 al aortic-valve replacement in patients with severe aortic stenosis and intermediate surgical risk.

70 is safe and well tolerated in patients with severe aortic stenosis and is associated with improvemen

71 ntravenous nitroprusside in 25 patients with severe aortic stenosis and left ventricular systolic dys

72 theter Valves) randomized 1000 patients with severe aortic stenosis and low surgical risk to undergo

73 We randomly assigned patients with severe aortic stenosis and low surgical risk to undergo

74 In patients with severe aortic stenosis and low surgical risk, TAVR with

75 Intervention) trial, all-comer patients with severe aortic stenosis and lower surgical risk for morta

76 le alternative for patients with symptomatic severe aortic stenosis and LV dysfunction who are at hig

77 In high-risk patients with severe aortic stenosis and LV dysfunction, mortality rat

78 In severe patients with severe aortic stenosis and LV dysfunction, transaortic v

79 For patients with asymptomatic severe aortic stenosis and normal left ventricular funct

80 In asymptomatic patients with severe aortic stenosis and preserved left ventricular ej

81 In asymptomatic patients with severe aortic stenosis and preserved left ventricular ej

82 ed in 1,490 patients (544 women [37%]), with severe aortic stenosis and preserved left ventricular ej

83 ess invasive treatment in many patients with severe aortic stenosis and since its introduction to the

84 te a pig model of heart failure secondary to severe aortic stenosis and to examine the relationship b

85 2015, consecutive patients with symptomatic, severe aortic stenosis and transthoracic echocardiograph

86 c valve replacement (SAVR) for patients with severe aortic stenosis and unfavorable iliofemoral acces

87 Patients had severe aortic stenosis and were at increased surgical ri

88 aortic-valve replacement in patients who had severe aortic stenosis and were at low surgical risk.

89 0) were considered to have medically managed severe aortic stenosis and were tracked over 5 years to

90 y hypertension (PH) frequently coexists with severe aortic stenosis, and PH severity has been shown t

91 ansfemoral TAVR for treatment of symptomatic severe aortic stenosis, and who were deemed to be at inc

92 ) and low-gradient (mean gradient <40 mm Hg) severe aortic stenosis (aortic valve area <1 cm(2)) with

93 Thirty-nine patients with asymptomatic severe aortic stenosis (aortic valve area <1 cm(2), peak

94 etrospectively identified 2017 patients with severe aortic stenosis (aortic valve area<1 cm(2), mean

95 ad a depressed ejection fraction (<or=0.35), severe aortic stenosis (aortic-valve area, <or=1 cm2), a

96 and treatment of patients with low-flow (LF) severe aortic stenosis are controversial.

97 73 +/- 7 years) with conventionally defined severe aortic stenosis area (aortic valve area </=1 cm(2

98 linical course of patients with asymptomatic severe aortic stenosis (AS) according to the new propose

99 eillance (CS) for patients with asymptomatic severe aortic stenosis (AS) and a normal left ventricula

100 ofiles and compare outcomes of patients with severe aortic stenosis (AS) and coronary artery disease

101 For patients with severe aortic stenosis (AS) and coronary artery disease

102 d quality-of-life outcomes for patients with severe aortic stenosis (AS) and high surgical risk treat

103 Patients with severe aortic stenosis (AS) and paradoxical low flow (PL

104 Among patients with severe aortic stenosis (AS) and preserved ejection fract

105 Older patients with severe aortic stenosis (AS) are increasingly identified

106 2-year safety and efficacy in patients with severe aortic stenosis (AS) at extreme risk of surgery t

107 In patients with severe aortic stenosis (AS) at intermediate surgical ris

108 In patients with severe aortic stenosis (AS) at intermediate surgical ris

109 In patients with severe aortic stenosis (AS) at low surgical risk, treatm

110 Patients with symptomatic severe aortic stenosis (AS) benefit from aortic valve re

111 Severe aortic stenosis (AS) can manifest as exertional a

112 low-gradient (LFLG) is sometimes observed in severe aortic stenosis (AS) despite normal ejection frac

113 ification of patients with low-gradient (LG) severe aortic stenosis (AS) despite preserved left ventr

114 Patients with severe aortic stenosis (AS) have repeat hospitalizations

115 Low-flow (LF) severe aortic stenosis (AS) is an independent predictor

116 of coronary artery disease in patients with severe aortic stenosis (AS) is posing challenges.

117 Severe aortic stenosis (AS) most often presents with red

118 Patients with severe aortic stenosis (AS) often have coronary artery d

119 tality in moderate to severe and paradoxical severe aortic stenosis (AS) patients with preserved ejec

120 ronary artery disease (CAD) in patients with severe aortic stenosis (AS) referred for transcatheter a

121 f intervention in patients with asymptomatic severe aortic stenosis (AS) remains controversial.

122 Among the first 72,631 patients with severe aortic stenosis (AS) treated with TAVR enrolled i

123 inical outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI.

124 fective therapeutic option for patients with severe aortic stenosis (AS) who are at prohibitive, high

125 We examined 1,154 patients with severe aortic stenosis (AS) who underwent AVR with or wi

126 we prospectively enrolled 105 patients with severe aortic stenosis (AS) who underwent TAVR as well a

127 Patients with severe aortic stenosis (AS) who were deemed too high ris

128 Background Paradoxical low-flow (LF) severe aortic stenosis (AS) with preserved left ventricu

129 receptor 1 and 2 levels in 21 patients with severe aortic stenosis (AS), in 26 patients with 3+ to 4

130 In severe aortic stenosis (AS), patients often show extra-a

131 valve replacement (AVR) among patients with severe aortic stenosis (AS), severe left ventricular (LV

132 d with a major benefit in high-gradient (HG) severe aortic stenosis (AS), the results in low-gradient

133 surgical aortic valve replacement (SAVR) for severe aortic stenosis (AS).

134 urgitation (MR) is frequent in patients with severe aortic stenosis (AS).

135 chnology for the management of patients with severe aortic stenosis (AS).

136 ic valve replacement (TAVR) in patients with severe aortic stenosis (AS).

137 r (LV) systolic dysfunction in patients with severe aortic stenosis (AS).

138 tein cholesterol (LDL-C) are associated with severe aortic stenosis (AS).

139 cardiomyopathy (ATTR-CM) often coexists with severe aortic stenosis (AS).

140 c valve replacement (SAVR) for patients with severe aortic stenosis (AS).

141 isease included changes in the definition of severe aortic stenosis (AS).

142 <=1.0 cm(2) is a defining characteristic of severe aortic stenosis (AS).

143 safe and effective therapy for patients with severe aortic stenosis (AS).

144 ship; 2) AVC thresholds best associated with severe aortic stenosis (AS); and 3) whether, in AS with

145 easonable in asymptomatic patients with very severe aortic stenosis (AS); however, the definition of

146 uary 2011 and August 2012, 639 patients with severe aortic stenosis at extreme surgical risk underwen

147 ly feasibility study including patients with severe aortic stenosis at high surgical risk undergoing

148 Patients with severe aortic stenosis at increased risk for surgery had

149 In patients with severe aortic stenosis at increased risk for surgery, se

150 panding valve found that among patients with severe aortic stenosis at increased risk for surgery, th

151 Patients with severe aortic stenosis at increased surgical risk contin

152 In patients with severe aortic stenosis at increased surgical risk, TAVR

153 rior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, wi

154 to assess TAVI in patients with symptomatic severe aortic stenosis at low operative risk have set th

155 Among patients with severe aortic stenosis at low or intermediate surgical r

156 e and effective in patients with symptomatic severe aortic stenosis at prohibitive risk for surgical

157 ssigned 2032 intermediate-risk patients with severe aortic stenosis, at 57 centers, to undergo either

158 dered to be contraindicated in patients with severe aortic stenosis because of concern that they may

159 A total of 5277 patients underwent AVR for severe aortic stenosis between 1992 and 2008.

160 rgoing surgical aortic valve replacement for severe aortic stenosis between 2012 and 2014 at our inst

161 lve replacement in symptomatic patients with severe aortic stenosis, but the impact of sex on outcome

162 bly accurate measure of AVA in patients with severe aortic stenosis compared to AVA(Fick) measured us

163 eas women presented more often with moderate/severe aortic stenosis compared with men.

164 Conclusions- Among inoperable patients with severe aortic stenosis, compared with standard care, TAV

165 e of particular importance for patients with severe aortic stenosis considering transcatheter aortic

166 Patients with severe aortic stenosis deemed at increased risk for surg

167 We evaluated 1023 patients with severe aortic stenosis deemed high or extreme risk for s

168 Controversy exists whether low gradient severe aortic stenosis despite preserved ejection fracti

169 Occurrence of low gradient severe aortic stenosis despite preserved ejection fracti

170 Surveillance for Patients With Asymptomatic Severe Aortic Stenosis [EARLY TAVR]; NCT03042104).

171 challenge in the management of patients with severe aortic stenosis, especially in elderly women, whe

172 thheld from symptomatic patients with LEF-LG severe aortic stenosis even in the presence of moderate

173 function, in intermediate-risk patients with severe aortic stenosis given transcatheter aortic valve

174 In asymptomatic patients with severe aortic stenosis, guidelines recommend left ventri

175 Although the prognosis and management of severe aortic stenosis has been extensively studied, the

176 The definition of severe aortic stenosis has classically and retrospective

177 h patients with high gradient (>/= 40 mm Hg) severe aortic stenosis (HGSAS) and moderate AS (mean gra

178 similar to that of patients with concordant severe aortic stenosis (HR: 0.98 [95% CI: 0.66-1.44]; P

179 Valve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk S

180 ((R)) System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk S

181 heter heart valve (THV) for the treatment of severe aortic stenosis in patients at extreme risk for s

182 VR is a new alternative for the treatment of severe aortic stenosis in patients at high risk for surg

183 d by the US Food and Drug Administration for severe aortic stenosis in patients who cannot undergo su

184 Current guidelines define severe aortic stenosis in patients with aortic valve are

185 antation is increasingly being used to treat severe aortic stenosis in patients with high operative r

186 0), patients with ECG strain (n=21) had more severe aortic stenosis, increased left ventricular mass

187 Untreated severe aortic stenosis is a progressive disease with a p

188 SAPIEN 3 in intermediate-risk patients with severe aortic stenosis is associated with low mortality,

189 catheter aortic valve replacement (TAVR) for severe aortic stenosis is growing rapidly.

190 from an asymptomatic to symptomatic state in severe aortic stenosis is often difficult to assess.

191 he pathophysiology of low flow, low gradient severe aortic stenosis (LGSAS) with preserved ejection f

192 Low-gradient severe aortic stenosis (LGSAS) with preserved ejection f

193 Agreement between severe aortic stenosis likelihood categories and CAC ris

194 ith end-stage lung disease in the setting of severe aortic stenosis, likely representing a better alt

195 of aortic valve replacement in patients with severe aortic stenosis, low transvalvular gradient, and

196 intermediate-risk patients with symptomatic severe aortic stenosis, major clinical outcomes at 5 yea

197 Patients with severe aortic stenosis may be deemed inoperable due to t

198 Asymptomatic patients with severe aortic stenosis may subconsciously curtail their

199 going TAVI, 113 (18.7%) patients with LEF-LG severe aortic stenosis (mean gradient </=40 mm Hg, aorti

200 The optimal management of low-gradient "severe" aortic stenosis (mean gradient <40 mm Hg, indexe

201 eter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus Edwar

202 dictors of an increased dilatation rate were severe aortic stenosis, moderate and severe aortic regur

203 bicuspid aortic valve stenosis, asymptomatic severe aortic stenosis, moderate aortic stenosis in comb

204 Patients with severe aortic stenosis (n = 61) underwent cardiac magnet

205 Asymptomatic patients with severe aortic stenosis (n=105; aortic valve area <0.6 cm

206 ompared the automated 3D TEE measurements in severe aortic stenosis (n=14), dilated root without aort

207 iomyopathy (n=34; 100% with LVH), those with severe aortic stenosis (n=21; 81% with LVH), and patient

208 son, in patients with conventionally defined severe aortic stenosis, orifice area by echo was 0.72 +/

209 k for rapid progression from mild or less to severe aortic stenosis over months, highlighting their n

210 of chronic lung disease (CLD) on outcomes of severe aortic stenosis patients across all treatment mod

211 Studies of TAVR in low-flow severe aortic stenosis patients have demonstrated that T

212 noninferior to TAVR with medical therapy in severe aortic stenosis patients with AF.

213 Severe aortic stenosis reduces the length and quality of

214 placement (TAVR) in inoperable patients with severe aortic stenosis remain unknown.

215 sis, and treatment of patients with low-flow severe aortic stenosis remains challenging.

216 Asymptomatic patients with severe aortic stenosis require frequent monitoring of th

217 low high gradient and low flow high gradient severe aortic stenosis (SAS) with no or minimal symptoms

218 Up to 30% of patients with severe aortic stenosis (SAS; indexed aortic valve area <

219 Why some but not all patients with severe aortic stenosis (SevAS) develop otherwise unexpla

220 y enrolled in the multicenter True or Pseudo-Severe Aortic Stenosis study, 126 patients with resting

221 In patients with symptomatic severe aortic stenosis, TAVI has now been explored acros

222 Among women with severe aortic stenosis, the incidence of the composite o

223 In asymptomatic patients with severe aortic stenosis, the main determinants of Ex-PHT

224 e to randomly assign high-risk patients with severe aortic stenosis to either SAVR or TAVR with a bal

225 ves (PARTNER) trial randomized patients with severe aortic stenosis to medical management versus tran

226 NER trial randomized high-risk patients with severe aortic stenosis to TAVR or SAVR.

227 , in a 1:1 ratio, patients with asymptomatic severe aortic stenosis to undergo early TAVR with transf

228 andomly assigned 699 high-risk patients with severe aortic stenosis to undergo either surgical aortic

229 andomly assigned 699 high-risk patients with severe aortic stenosis to undergo either transcatheter a

230 pectively enrolled patients with symptomatic severe aortic stenosis to undergo TAVR using a commercia

231 In high-risk patients with severe aortic stenosis, transcatheter and surgical proce

232 In patients with severe aortic stenosis, transcatheter aortic valve repla

233 ial load were measured in 2141 patients with severe aortic stenosis treated with TAVR in the PARTNER

234 ropean prospective registry of patients with severe aortic stenosis treated with the commercially ava

235 y QFR can predict mortality in patients with severe aortic stenosis treated with transcatheter aortic

236 of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment (OBSERVANT) study.

237 ness of TAVI With New Generation Devices for Severe Aortic Stenosis Treatment) from December 2016 to

238 of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) showed that mortality

239 of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) trial is an observatio

240 among high-risk and inoperable patients with severe aortic stenosis undergoing a transcatheter aortic

241 werful predictor of outcome in patients with severe aortic stenosis undergoing aortic valve replaceme

242 In patients with symptomatic severe aortic stenosis undergoing aortic valve replaceme

243 Elderly patients with severe aortic stenosis undergoing medical management hav

244 r interactions on mortality in patients with severe aortic stenosis undergoing surgical aortic valve

245 clinical trial in higher-risk patients with severe aortic stenosis undergoing TAVI at the University

246 Among patients with severe aortic stenosis undergoing TAVI, the use of a cer

247 In patients with severe aortic stenosis undergoing TAVR, even with baseli

248 edium-term mortality rates for patients with severe aortic stenosis undergoing transcatheter aortic v

249 AF is common among high-risk patients with severe aortic stenosis undergoing transcatheter aortic v

250 disease is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic v

251 y-four consecutive patients with inoperable, severe aortic stenosis underwent TAO TAVR in our institu

252 1 years, log EuroSCORE: 25.0 +/- 15.0%) with severe aortic stenosis underwent transfemoral TAVI at 2

253 Minnesota) was implanted in 10 patients with severe aortic stenosis utilizing percutaneous femoral ar

254 Patients undergoing AVR for severe aortic stenosis were analyzed using the Northern

255 One hundred high surgical risk patients with severe aortic stenosis were evaluated for the primary en

256 tal of 1,414 low-surgical risk patients with severe aortic stenosis were randomized to receive TAVR o

257 to July 2009, a cohort of 362 patients with severe aortic stenosis were screened and did not meet th

258 an or equal to III+ aortic regurgitation and severe aortic stenosis were seen in 37% and 10%, respect

259 moderate to severe aortic regurgitation, and severe aortic stenosis were seen in 7%, 18%, and 2%, whe

260 hed pairs of intermediate-risk patients with severe aortic stenosis were studied.

261 rtic sclerosis; 25 mild, 33 moderate, and 23 severe aortic stenosis) were administered both 18F-NaF a

262 Patients had severe aortic stenosis, were treated with TAVR or SAVR,

263 fective therapy in symptomatic patients with severe aortic stenosis, whereas the management of asympt

264 ension frequently coexists with low-gradient severe aortic stenosis, which itself may cause elevated

265 acement (SAVR) for patients with symptomatic severe aortic stenosis who are at high risk of periopera

266 pted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, le

267 tiveness of the Lotus valve in patients with severe aortic stenosis who are at high surgical risk.

268 w method to treat patients with symptomatic, severe aortic stenosis who are at high surgical risk.

269 (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk.

270 s an alternative to surgery in patients with severe aortic stenosis who are at increased risk for dea

271 In patients with severe aortic stenosis who are at increased surgical ris

272 In patients with severe aortic stenosis who are at increased surgical ris

273 od 30 day clinical outcomes in patients with severe aortic stenosis who are at intermediate risk of s

274 s currently being evaluated in patients with severe aortic stenosis who are considered high-risk surg

275 For patients with severe aortic stenosis who are not candidates for surger

276 is the recommended therapy for patients with severe aortic stenosis who are not suitable candidates f

277 ) is an accepted treatment for patients with severe aortic stenosis who are not suitable for surgery.

278 eter heart valve (THV) size in patients with severe aortic stenosis who are suboptimal surgical candi

279 In patients with severe aortic stenosis who cannot have surgery, transcat

280 pared with standard therapy in patients with severe aortic stenosis who cannot have surgery.

281 Patients from 10 institutions with severe aortic stenosis who underwent TAVR between August

282 vational cohort study included patients with severe aortic stenosis who underwent TAVR in the Society

283 Patients with severe aortic stenosis who were at increased surgical ri

284 We recruited patients with severe aortic stenosis who were at increased surgical ri

285 In patients with severe aortic stenosis who were at low surgical risk, TA

286 Among patients with severe aortic stenosis who were at low surgical risk, th

287 trial randomized patients with symptomatic, severe aortic stenosis who were not candidates for surge

288 trial randomized patients with symptomatic, severe aortic stenosis who were not candidates for surgi

289 Among appropriately selected patients with severe aortic stenosis who were not suitable candidates

290 In patients with severe aortic stenosis who were not suitable candidates

291 tudy involved 300 patients with asymptomatic severe aortic stenosis who were seen in the ambulatory M

292 We randomly assigned patients with severe aortic stenosis, whom surgeons considered not to

293 3.2 million (95% CI, 2.2-4.4) patients have severe aortic stenosis with 1.9 million (95% CI, 1.3-2.6

294 We compared outcomes of low-gradient severe aortic stenosis with AVR or medical therapy.

295 unctional status in inoperable patients with severe aortic stenosis with durable hemodynamic benefit

296 the management of patients with low-gradient severe aortic stenosis with preserved ejection fraction

297 Low-gradient severe aortic stenosis with preserved ejection fraction

298 Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction

299 -expanding TAVR in patients with symptomatic severe aortic stenosis with prohibitive risks for surger

300 o undergo aortic valve replacement (AVR) for severe aortic stenosis with reduced preoperative ejectio